Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review
Acta Haematologica Polonica · 29.10.2026 · 57 (5) · 380-389
DOI: 10.5603/ahp.112557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica Polonica, online erschienen am 29.10.2026. Verfasst von Wojciech Maciej Legiec und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Legiec, W. M., Vesole, D. H., & Jurczyszyn, A. (2026). Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review. Acta Haematologica Polonica, 57(5), 380-389. https://doi.org/10.5603/ahp.112557
Vancouver
Legiec WM, Vesole DH, Jurczyszyn A. Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review. Acta Haematologica Polonica. 2026;57(5):380-389. doi:10.5603/ahp.112557
BibTeX
@article{Legiec2026,
author = {Legiec, Wojciech Maciej and Vesole, David H. and Jurczyszyn, Artur},
title = {Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review},
journal = {Acta Haematologica Polonica},
year = {2026},
volume = {57},
number = {5},
pages = {380--389},
doi = {10.5603/ahp.112557}
}
EUVIMED